Free Trial
OTCMKTS:BAYRY

Bayer Aktiengesellschaft 11/8/2023 Earnings Report

Bayer Aktiengesellschaft logo
$7.98 -0.14 (-1.72%)
As of 07/11/2025 03:58 PM Eastern

Bayer Aktiengesellschaft EPS Results

Actual EPS
$0.10
Consensus EPS
$0.20
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Bayer Aktiengesellschaft Revenue Results

Actual Revenue
$11.26 billion
Expected Revenue
$12.62 billion
Beat/Miss
Missed by -$1.36 billion
YoY Revenue Growth
N/A

Bayer Aktiengesellschaft Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bayer Aktiengesellschaft's next earnings date is estimated for Tuesday, August 5, 2025, based on past reporting schedules.

Conference Call Resources

Bayer Aktiengesellschaft Earnings Headlines

Bayer Leverkusen confirm Tillman capture
🚨 Bayer Leverkusen sign Malik Tillman
A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
See More Bayer Aktiengesellschaft Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bayer Aktiengesellschaft? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bayer Aktiengesellschaft and other key companies, straight to your email.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) is a German multinational life sciences company headquartered in Leverkusen, Germany. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company initially gained recognition for the synthesis of synthetic dyes before broadening its focus to health and agriculture. Today, Bayer operates through four main business segments—pharmaceuticals, consumer health, crop science, and animal health—serving customers in more than 83 countries worldwide.

The pharmaceutical division of Bayer develops and markets prescription medicines in areas such as cardiology, oncology, women’s health, and hematology. Notable products include Xarelto, Eylea, and Kogenate, which address conditions ranging from cardiovascular disease to retinal disorders and blood clotting deficiencies. Bayer’s research and development efforts in this segment emphasize targeted therapies, gene editing technologies, and novel drug delivery systems to meet evolving patient needs.

Bayer’s consumer health unit offers a diverse portfolio of over-the-counter products covering pain relief, allergy relief, dermatology, and nutritional supplements. Iconic brands like Aspirin, Claritin, and Bepanthen underscore the company’s long-standing commitment to everyday wellness. The crop science division delivers seeds, crop protection solutions, and digital farming tools designed to enhance agricultural productivity and sustainability, bolstered by acquisitions such as Monsanto and ongoing investments in biotech and precision agriculture.

Under the leadership of Chief Executive Officer Bill Anderson, Bayer continues to strengthen its innovation pipeline through strategic partnerships, acquisitions, and internal R&D programs. The company maintains a global workforce dedicated to scientific discovery, regulatory compliance, and community engagement. By integrating its pharmaceutical and agricultural expertise, Bayer aims to address critical challenges such as chronic disease management, food security, and environmental stewardship on a global scale.

View Bayer Aktiengesellschaft Profile

More Earnings Resources from MarketBeat